A federal judge has ruled that hundreds of Fosamax femur fracture lawsuits are preempted by federal law because the FDA rejected a proposed warning label change.
A new study reveals that Fosamax and similar osteoporosis drugs failed to provide any benefits in preventing hip fractures after seven years of use.
A new study warns that Fosamax and similar drugs greatly increase the risk of atypical femur fractures after more than five years of use.
About 500 Fosamax bone fracture lawsuits have been remanded to a New Jersey federal court, for a district judge to decide if they are preempted by federal law.
The Supreme Court has remanded about 500 Fosamax lawsuits back to a lower court, saying if Merck cannot prove it gave the FDA adequate information to decide on femur fracture…
A product liability lawsuit claims that a DePuy Synthes femur plate failed twice, resulting in injuries and metal blood poisoning.
The Supreme Court has agreed to hear Merck's appeal of the Fosamax femur fracture litigation reinstatement, and a decision could have widespread implications for drug liability lawsuits.
A decision to reinstate more than 1,100 Fosamax femur fracture lawsuits may go before the Supreme Court.
A new study appears to show the mechanism of action that may cause bone-strengthening drugs like Fosamax to increase the risk of femur fractures.
Fosamax femur fracture litigation, which was effectively dead following a 2015 summary judgment, has been resurrected by an Appeals Court decision that reinstates hundreds of lawsuits.
